Campbell University, College of Pharmacy & Health Sciences, Department of Pharmaceutical Sciences, PO Box 1090, Buies Creek, NC 27506, USA.
Campbell University, College of Pharmacy & Health Sciences, Department of Pharmaceutical Sciences, PO Box 1090, Buies Creek, NC 27506, USA; Campbell University, College of Pharmacy & Health Sciences, Pharmaceutical Education & Research Center, 130 Burt Street, Buies Creek, NC 27506, USA.
Int J Pharm. 2018 Jan 15;535(1-2):172-179. doi: 10.1016/j.ijpharm.2017.10.034. Epub 2017 Oct 20.
The purpose of this research was to determine acyclovir (ACV) acidic degradation kinetics which is relevant to gastric retentive device product design. A stability-indicating method revealed two unknown degradation products which have been identified by mass spectrometry as ACV and guanine formaldehyde adducts. In addition to the formation of these adducts, a proposed degradation scheme identifies the formation of methyl acetal ethylene glycol, formaldehyde, ethylene glycol, and guanine as additional ACV degradation products. pH-rate profiles were explained by using a rate law which assumed acid-catalyzed hydrolysis of protonated and unprotonated ACV. The predicted and observed rate constants were in good agreement. Data-driven excipient selection recommendations were based on the chemical kinetic study results, degradation scheme, and pH-rate profiles. The average activation energy for the degradation reaction was determined to be 31.3±1.6kcal/mol. The predicted ACV t at 37°C and pH 1.2 was calculated to be 7.2days. As a first approximation, this suggests that ACV gastric retentive devices designed to deliver drug for 7days should have acceptable drug product stability in the stomach.
本研究旨在确定与胃滞留装置产品设计相关的阿昔洛韦(ACV)酸性降解动力学。一种稳定性指示方法揭示了两种未知的降解产物,通过质谱鉴定为 ACV 和鸟嘌呤甲醛加合物。除了这些加合物的形成外,提出的降解方案还确定了甲基乙缩醛乙二醇、甲醛、乙二醇和鸟嘌呤作为 ACV 降解产物的形成。通过使用假定质子化和非质子化 ACV 酸催化水解的速率定律来解释 pH-速率曲线。预测和观察到的速率常数非常吻合。基于化学动力学研究结果、降解方案和 pH-速率曲线,提出了基于数据的赋形剂选择建议。降解反应的平均活化能确定为 31.3±1.6kcal/mol。预测的 ACV 在 37°C 和 pH 1.2 下的 t 为 7.2 天。作为初步估计,这表明设计用于在胃中输送药物 7 天的 ACV 胃滞留装置在胃中应具有可接受的药物稳定性。